EP3618819A4 - TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT - Google Patents

TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT Download PDF

Info

Publication number: EP3618819A4
Authority: EP; European Patent Office
Prior art keywords: procedures; combinations; novel compositions; targeted drug; drug rescue
Prior art date: 2017-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP18794381.6A

Other languages

German (de)

French (fr)

Other versions

EP3618819A1 (en

Inventor

Sreenivasarao Vepachedu

Hans J. MOEBIUS

Anton Bespalov

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Exciva GmbH

Original Assignee

Exciva GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-04

Filing date

2018-05-03

Publication date

2021-01-20

2017-08-25 Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en

2018-05-03 Application filed by Exciva GmbH filed Critical Exciva GmbH

2020-03-11 Publication of EP3618819A1 publication Critical patent/EP3618819A1/en

2021-01-20 Publication of EP3618819A4 publication Critical patent/EP3618819A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP18794381.6A 2017-05-04 2018-05-03 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT Pending EP3618819A4 (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US201762501696P	2017-05-04	2017-05-04
PCT/US2017/048748 WO2018039642A1 (en)	2016-08-26	2017-08-25	Compositions and methods thereof
TW106129169A TW201815387A (en)	2016-08-26	2017-08-28	Compositions and methods thereof
US201862634162P	2018-02-22	2018-02-22
US201862636099P	2018-02-27	2018-02-27
US201862635554P	2018-02-27	2018-02-27
US201862636171P	2018-02-28	2018-02-28
PCT/US2018/030978 WO2018204713A1 (en)	2017-05-04	2018-05-03	Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (2)

Publication Number	Publication Date
EP3618819A1 EP3618819A1 (en)	2020-03-11
EP3618819A4 true EP3618819A4 (en)	2021-01-20

Family

ID=65431106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18794381.6A Pending EP3618819A4 (en)	2017-05-04	2018-05-03	TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT

Country Status (13)

Country	Link
EP (1)	EP3618819A4 (en)
JP (2)	JP7514078B2 (en)
KR (2)	KR20200062078A (en)
CN (1)	CN110831584B (en)
AU (2)	AU2018261654A1 (en)
BR (1)	BR112019022902A2 (en)
CA (2)	CA3138116A1 (en)
IL (1)	IL270326B2 (en)
MA (1)	MA49464A (en)
RU (1)	RU2760558C9 (en)
TW (1)	TWI787260B (en)
WO (1)	WO2018204713A1 (en)
ZA (1)	ZA201908006B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7514078B2 (en) *	2017-05-04	2024-07-10	エクシーバゲーエムベーハー	Targeted drug rescue using novel compositions, combinations and methods thereof
TW202102219A (en) *	2019-03-18	2021-01-16	美商艾賓爾製藥公司	Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
WO2020246143A1 (en) *	2019-06-06	2020-12-10	Jsr株式会社	Radiation-sensitive resin composition, resist pattern formation method, and compound
AU2021276656A1 (en)	2020-05-19	2022-11-24	Cybin Irl Limited	Deuterated tryptamine derivatives and methods of use
CN116473077B (en) *	2023-05-08	2025-04-11	广东方中高新材料有限公司	Synthesis and application of an N,N coordinated gallium complex antibacterial agent
CN116473073A (en) *	2023-05-08	2023-07-25	广东方中高新材料有限公司	Pyraclostrobin synergistic suspension preparation containing gallium complex and preparation method thereof
CN119432479B (en) *	2023-08-04	2025-10-03	中国石油天然气股份有限公司	Diesel engine lubricating oil composition and preparation method thereof
CN120987847A (en) *	2024-11-29	2025-11-21	江苏恩华药业股份有限公司	Dextromethorphan hydrobromide preparation method of sand

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004006930A1 (en) *	2002-07-17	2004-01-22	Avanir Pharmaceuticals	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2008137474A1 (en) *	2007-05-01	2008-11-13	Concert Pharmaceuticals Inc.	Morphinan compounds
WO2014011590A2 (en) *	2012-07-12	2014-01-16	Javitt Daniel C	Composition and method for treatment of depression and psychosis in humans

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4241065A (en) *	1979-07-02	1980-12-23	E. I. Du Pont De Nemours And Company	Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) *	1988-12-06	1990-08-21	Board Of Trustees Of Southern Illinois Univ.	Method of medical treatment of Alzheimer's disease
US5891885A (en) *	1996-10-09	1999-04-06	Algos Pharmaceutical Corporation	Method for treating migraine
US6207674B1 (en) *	1999-12-22	2001-03-27	Richard A. Smith	Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) *	2000-11-28	2002-01-01	Orion Corporation	Method for inducing cognition enhancement
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2008009947A (en)	2006-02-03	2008-10-20	Avanir Pharmaceuticals	Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders.
AU2008254585B2 (en) *	2007-05-21	2013-09-26	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) *	2008-07-03	2011-09-13	Trinity Laboratories, Inc.	Dextromethorphan hydrochloride
EP2964022B1 (en) *	2013-03-07	2019-11-06	Mindlab LLC	Pain medicine combination and uses thereof
CA2907357A1 (en) *	2013-03-15	2014-09-18	Kinemed, Inc.	Biomarkers
SG11201701645WA (en) *	2014-09-14	2017-04-27	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
JP7096813B2 (en) *	2016-08-26	2022-07-06	エクシーバゲーエムベーハー	Composition and method thereof
JP7514078B2 (en) *	2017-05-04	2024-07-10	エクシーバゲーエムベーハー	Targeted drug rescue using novel compositions, combinations and methods thereof

2018
- 2018-05-03 JP JP2019560216A patent/JP7514078B2/en active Active
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/en active Active
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/en not_active Ceased
- 2018-05-03 MA MA049464A patent/MA49464A/en unknown
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en not_active Ceased
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/en active Active
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/en not_active Application Discontinuation
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/en active
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-04 TW TW107115320A patent/TWI787260B/en active
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004006930A1 (en) *	2002-07-17	2004-01-22	Avanir Pharmaceuticals	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2008137474A1 (en) *	2007-05-01	2008-11-13	Concert Pharmaceuticals Inc.	Morphinan compounds
WO2014011590A2 (en) *	2012-07-12	2014-01-16	Javitt Daniel C	Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296 *
MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024 *
See also references of WO2018204713A1 *
SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141 *

Also Published As

Publication number	Publication date
CN110831584B (en)	2023-03-10
KR102444803B1 (en)	2022-09-19
BR112019022902A2 (en)	2020-05-19
AU2018261654A1 (en)	2019-11-14
JP7514078B2 (en)	2024-07-10
IL270326B2 (en)	2023-02-01
CA3062452A1 (en)	2018-11-08
KR20210130827A (en)	2021-11-01
JP2020518617A (en)	2020-06-25
CA3062452C (en)	2023-10-24
ZA201908006B (en)	2021-04-28
JP2023143940A (en)	2023-10-06
TWI787260B (en)	2022-12-21
RU2760558C9 (en)	2022-02-22
RU2019137004A3 (en)	2021-06-04
WO2018204713A1 (en)	2018-11-08
IL270326A (en)	2018-05-03
CA3138116A1 (en)	2018-11-08
CN110831584A (en)	2020-02-21
TW201842902A (en)	2018-12-16
EP3618819A1 (en)	2020-03-11
MA49464A (en)	2020-04-29
RU2760558C2 (en)	2021-11-29
KR20200062078A (en)	2020-06-03
RU2019137004A (en)	2021-06-04
AU2021215274A1 (en)	2021-09-02
AU2021215274B2 (en)	2022-11-03
IL270326B (en)	2022-10-01

Publication	Publication Date	Title
EP3463386A4 (en)	2020-03-04	OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR
EP3618819A4 (en)	2021-01-20	TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT
EP3599868A4 (en)	2020-12-02	HERBICIDE MIXTURE, COMPOSITION AND PROCEDURE
EP3827846C0 (en)	2024-10-02	COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY
EP3436482A4 (en)	2020-03-11	ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
EP3217046C0 (en)	2024-05-01	ORDER AND RELATED PROCEDURES
EP3513809A4 (en)	2020-06-03	MEDICINAL COMPOSITION
LT3426226T (en)	2022-07-25	OPHTHALMOLOGICAL COMPOSITION
HUE052095T2 (en)	2021-04-28	Keratin treatment compositions and methods
CL2016002569A1 (en)	2017-09-08	Antibodies, pharmaceutical compositions and uses thereof
DK3655038T3 (en)	2025-02-17	PHARMACEUTICAL COMPOSITION
BR112016018062A2 (en)	2017-08-08	therapeutic compounds, pharmaceutical composition and uses
EP3724211A4 (en)	2021-10-27	DOSING PLANS, ASSOCIATED COMPOSITIONS AND PROCEDURES
LT3273947T (en)	2019-07-10	COMPOSITION FOR EYE HEALTH
DK3275452T3 (en)	2021-04-19	PHARMACEUTICAL COMPOSITION WITH SILIBININE
DK3236934T3 (en)	2024-08-19	PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF
EP3302478A4 (en)	2019-02-27	PAC-1 BASED POLY THERAPY
DK3583943T3 (en)	2024-10-14	PHARMACEUTICAL COMPOSITION
BR112017013012A2 (en)	2018-06-26	indenyl compounds, pharmaceutical compositions and medical uses thereof
EP3625234A4 (en)	2021-03-10	COMPOUNDS, COMPOSITIONS AND PROCEDURES
DK3313370T3 (en)	2021-03-29	Ophthalmological pharmaceutical composition
EP3738601A4 (en)	2021-06-16	CYTOCIDAL AGENT
SMT202400478T1 (en)	2025-01-14	PHARMACEUTICAL COMPOSITION
EP3702404A4 (en)	2020-11-11	POLYMER COMPOSITION AND TIRE
EP3703675A4 (en)	2021-06-16	SUBSTITUTED PHENYLSULFONYLPHENYLTRIAZOLTHIONES AND USES THEREOF

Legal Events

Date	Code	Title	Description
2018-11-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-02-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-02-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-03-11	17P	Request for examination filed	Effective date: 20191203
2020-03-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-03-11	AX	Request for extension of the european patent	Extension state: BA ME
2020-08-12	DAX	Request for extension of the european patent (deleted)
2020-08-12	RAV	Requested validation state of the european patent: fee paid	Extension state: MA Effective date: 20191203 Extension state: TN Effective date: 20191203
2020-08-28	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40015233 Country of ref document: HK
2020-12-11	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031135000 Ipc: A61K0031138000
2021-01-20	A4	Supplementary search report drawn up and despatched	Effective date: 20201217
2021-01-20	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/225 20060101ALI20201211BHEP Ipc: A61K 47/60 20170101ALI20201211BHEP Ipc: A61K 9/20 20060101ALI20201211BHEP Ipc: A61K 47/36 20060101ALI20201211BHEP Ipc: A61K 31/485 20060101ALI20201211BHEP Ipc: A61K 31/195 20060101ALI20201211BHEP Ipc: A61K 45/06 20060101ALI20201211BHEP Ipc: A61K 31/13 20060101ALI20201211BHEP Ipc: A61K 31/138 20060101AFI20201211BHEP Ipc: A61P 25/00 20060101ALI20201211BHEP Ipc: A61K 31/439 20060101ALI20201211BHEP Ipc: A61P 9/00 20060101ALI20201211BHEP
2023-11-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-12-27	17Q	First examination report despatched	Effective date: 20231123